Serum SYPL1 might be an outstanding marker for CRC diagnosis, especially for patients with low CEA levels [15], and fecal SYPL1 might be a potential biomarker for CRC screening, early diagnosis, prediction and therapeutic effect monitoring [12]. Here, CEACAM5 is linked to colorectal carcinoma.